Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.4% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
8
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.4% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Shield Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Single Asset Dependency And US Pricing Challenges Will Mar Prospects
Key Takeaways Dependence on a single product and increasing generic competition heighten vulnerability to revenue loss and market share erosion. Pricing pressures, restrictive reimbursement, and rising regulatory demands threaten margin sustainability and long-term profitability.
View narrative
UK£0.032
FV
103.1% overvalued
intrinsic discount
49.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
DarioHealth
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Digital Health Onboarding Delays And Rising Costs Will Ease Eventually
Key Takeaways Persistent onboarding delays and client turnover risk short-term revenue, while macroeconomic uncertainty and enterprise budget constraints may limit new customer growth. Margin gains via AI and analytics are offset by the need for sustained R&D investment and sector challenges that delay profitability and consistent earnings growth.
View narrative
US$0.60
FV
25.0% undervalued
intrinsic discount
9.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Wisr
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Australian Lending Risks Will Strain Margins Yet Allow Recovery
Key Takeaways Increased regulatory scrutiny, dependence on wholesale funding, and cost-of-living pressures could restrict loan growth, compress margins, and heighten default risks. Rising competition from tech players and demographic shifts may erode Wisr's market share, limit pricing power, and cap long-term revenue expansion.
View narrative
AU$0.067
FV
55.2% undervalued
intrinsic discount
112.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Longeveron
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
Key Takeaways Heavy dependence on successful clinical approvals and external funding exposes Longeveron to significant revenue and operational uncertainty. Rising expenses, limited cash runway, and uncertain commercialization prospects increase the risk of future dilution and financial instability.
View narrative
US$3.00
FV
73.0% undervalued
intrinsic discount
143.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Co-Diagnostics
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
Key Takeaways High execution risk and regulatory uncertainty threaten the company's ability to turn innovation into timely commercial gains, while persistent losses pressure financial sustainability. Intense competition, pricing pressures, and regulatory compliance challenges may hamper expansion, reduce margins, and limit market penetration in both domestic and international markets.
View narrative
US$1.00
FV
68.0% undervalued
intrinsic discount
279.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Starbreeze
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
High Gaming Concentration Will Strain Performance Yet Allow Recovery
Key Takeaways Heavy reliance on the PAYDAY franchise limits revenue diversification and heightens risk if new content or transmedia efforts underperform. Regulatory pressures on digital monetization and rising industry competition may constrain profitability and challenge the sustainability of recurring revenue streams.
View narrative
SEK 0.26
FV
26.8% undervalued
intrinsic discount
15.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Oncopeptides
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
European Pricing And Regulatory Pressures Will Erode Value
Key Takeaways Reliance on a single product and tougher regulatory standards heighten financial and operational risks, risking abrupt drops in sales and delayed growth. Competitive pressures, shrinking pricing power, and constrained funding threaten market share, margin stability, and the company's long-term financial health.
View narrative
SEK 1.70
FV
228.8% overvalued
intrinsic discount
117.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Worksport
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Commercialization Delays Will Strain Margins Yet Reveal Hidden Value
Key Takeaways Worksport's growth hinges on successful new product launches, but ongoing operating losses and cash burn could necessitate external funding, raising dilution risks. Margins and future revenue face pressure from supply chain costs and auto industry trends, while major product commercialization remains unproven.
View narrative
US$7.00
FV
56.3% undervalued
intrinsic discount
83.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Vivos Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Increasing Regulation And Telemedicine Will Limit Future Prospects
Key Takeaways Rising regulatory costs, digital health trends, and payer resistance threaten revenue growth and profitability for Vivos' device-based treatments. Competitive pressures and innovation in alternative therapies risk making Vivos' offerings obsolete, challenging long-term market relevance and financial sustainability.
View narrative
US$2.25
FV
97.8% overvalued
intrinsic discount
18.81%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies